of approximately 11 hours. 5 Superior antihypertensive efficacy to valsartan and olmesartan has been demonstrated in three clinical trials [6] [7] [8] ; this greater efficacy may be related to the more potent and persistent binding of AZL to the angiotensin II type 1 receptor relative to other ARBs. 9, 10 From prior pivotal studies evaluating the safety and efficacy of AZL-M vs placebo and other ARBs, 6 -8 a subgroup analysis in AA patients demonstrated significant reductions in 24-hour systolic BP (SBP) vs placebo. 11 The present trial was a dedicated study in AAs with stages 1 and 2 hypertension designed to evaluate both the efficacy and safety of AZL-M vs. placebo in this population. The primary end point was the change in 24-hour mean SBP, as determined by ambulatory BP monitoring (ABPM). Given the high prevalence of hypertension and the lower efficacy rates of ARBs in AA patients, as well as the underrepresentation of AAs in hypertension clinical trials, this study addressed an important medical need.
| METHODS

| Patients and study design
This was a 6-week, randomized, double-blind, multicenter, placebocontrolled study comparing the antihypertensive effects and safety and tolerability of AZL-M, 40 or 80 mg once daily, with placebo in AA patients with stages 1 or 2 systolic hypertension. The protocol conformed to the Declaration of Helsinki and regional regulatory guidelines, and the study was approved by regional institutional review boards (IRBs). Each patient signed an IRB-approved consent form before any study procedures were initiated. Eligible patients were randomized after participating in a 3-to 4-week washout of previous antihypertensive therapy that coincided with a 2-week single-blind, placebo run-in period.
At randomization, each patient was required to be 18 years or older, with a clinic SBP ≥150 and ≤180 mm Hg and a 24-hour mean SBP ≥130
and ≤170 mm Hg. Exclusion criteria included known or suspected secondary hypertension or severe diastolic hypertension (seated diastolic
[DBP] >114 mm Hg); severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m 2 ); history of a major cardiovascular event in the previous 6 months; type 1 or poorly controlled type 2 diabetes mellitus (glycated hemoglobin >8%); poor compliance with study medication during the placebo run-in period; or hyperkalemia (serum potassium concentration>upper limit of normal for the reference laboratory). In addition, night-shift workers, pregnant or nursing women, and women of childbearing potential not using approved means of contraception were excluded from participation. Concomitant medications known to affect BP were not permitted; these medications were listed in the protocol and available to all study personnel.
Seated BP was measured in the clinic at baseline and at weeks 2, 4, and 6, and ABPM was performed at baseline and week 6. Clinic BP was measured in triplicate in the nondominant arm using an auto- 
| Statistical analyses
The primary end point was change from baseline to week 6 in 24 All statistical tests were two-sided and results were presented as treatment differences with 95% confidence intervals (CIs) and P values at the 5% significance level. Type 1 error was controlled for the primary analysis by using the principle of "closed" testing. 12 For the key secondary efficacy variable, the same statistical model and testing procedure used for the primary end point were used. Given the assumptions of a standard deviation of 13 mm Hg and a 20% dropout rate, the sample size of this study provided at least 90% power to de- 
| RESULTS
A total of 1266 patients were screened, and 916 patients were en- 
| Efficacy findings
The absolute changes from baseline on ambulatory BP after 6 weeks of therapy for all the treatments are shown in 
| Safety findings
Rates of treatment-emergent adverse events were comparable in the three treatment groups (Table 2) . Treatment-emergent adverse events were generally mild to moderate in severity. The most common adverse events during the trial were headache, increased creatine phosphokinase, and urinary tract infection ( There were no deaths in the trial.
There were no differences in mean changes in serum creatinine, potassium, or liver enzymes observed among the three treatment groups. No participant experienced serum potassium >6 mmol/L. One participant (0.7%) in the placebo treatment group and one participant in the 80-mg treatment group had an increase in serum creatinine ≥50% above baseline and above the upper limit of normal. There were no instances of a persistent increase in serum creatinine following discontinuation of study drug.
| DISCUSSION
The results of this trial demonstrate that AZL-M produced significant BP-lowering effects throughout the dosing interval in AA patients with hypertension and was well tolerated. The reductions in ambulatory and clinic BPs from baseline were highly significant and clinically important, showing greater dose-related reductions for 80 mg vs 40 mg in this patient population.
There has been a longstanding impression that RAS inhibitors are much less efficacious in AA patients with hypertension when compared with their white counterparts (which is clearly the case for a number of agents, including telmisartan, another fairly long-acting ARB). These impressions were based on the theory that the RAS is less active in AAs vs whites because of the tendency towards suppressed circulating renin activity in AAs 13, 14 and the lesser average BP response in AA as compared with white hypertensive patients to ACEIs when used as monotherapy. 1, [15] [16] [17] [18] However, circulating renin levels are not fully suppressed in the majority of AAs. 19 Also, suppressed renin production and circulating renin levels from high sodium intake have been associated with higher levels of vascular angiotensin II production 20 and a greater activation of RAS in healthy AAs as compared with whites. 21 The excessive rates of target organ injury such as chronic kidney disease and proteinuria in hypertensive AAs have all been associated with RAS activation, 22 which supports the evidence from prior studies demonstrating that ACEIs and ARBs are effective antihypertensives for slowing the progression of kidney disease in patients with diabetic and nondiabetic chronic kidney disease. [23] [24] [25] [26] [27] The basis for the primary use of ACEIs in the AA population with hypertension 
| CONCLUSIONS
The results from our study demonstrate that an ARB with potent efficacy such as AZL-M was able to provide clinically meaningful reductions in ambulatory and clinic BP when used as monotherapy in AA patients. It is also noteworthy that use of AZL-M shows greater efficacy in AA patients when combined with other types of antihypertensives, particularly the long-acting diuretic chlorthalidone and the long-acting dihydropyridine calcium channel blocker amlodipine. [31] [32] [33] Race and/or ethnicity should not be a deterrent to clinicians for using ARBs as evidenced by our data. AZL-M can be considered as a potentially effective and well-tolerated monotherapy or in combination with other therapy for this often difficult to manage population. 
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